Your AI-Trained Oncology Knowledge Connection!

New Treatment Options for DLBCL: Impact on Sequencing Therapeutic Choices : Episode 9

Opinion

Video

February 6, 2024

Navigating Toxicities in CAR T-Cell Therapy in R/R DLBCL

Author(s):

Clinical Oncologists focus their discussion on navigating toxicities specific to CAR T, highlighting cytokine release syndrome (CRS) and neurotoxicities.

EP: 1.Overview of First-Line Treatment in Diffuse Large B-Cell Lymphoma

EP: 2.Evolving Practice Standards and Disease Progression Beyond Frontline Therapy for Patients with DLBCL

EP: 3.Treatment Selection in Second Line R/R DLBCL

EP: 4.Tafasitamab and Lenalidomide for R/R DLBCL

EP: 5.Real-World Outcomes of Tafasitamab-Lenalidomide for Patients with R/R DLBCL

EP: 6.The Role of CAR T-Cell Therapy in R/R DLBCL

EP: 7.Data Updates: CAR T in the ZUMA-7 and TRANSFORM Trials for R/R DLBCL

EP: 8.Clinical Perspectives of CAR T in R/R Diffuse Large B-Cell Lymphoma

Now Viewing

EP: 9.Navigating Toxicities in CAR T-Cell Therapy in R/R DLBCL

EP: 10.Relapsed/Refractory DLBCL: Therapeutic Options in the Third Line Setting

EP: 11.Bispecifics for Third Line Therapy of R/R DLBCL

EP: 12.R/R DLBCL: Safety Considerations for Bispecific Antibodies

EP: 13.Treatment Sequencing of Later Line Therapies in R/R DLBCL

EP: 14.Additional Data Updates from ASH 2023

EP: 15.Future Outlooks in the Treatment of R/R DLBCL

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All

Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity

Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity

Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity

Latest Conference Coverage

GI Cancer Experts on Notable Updates Shared During the 2025 ASCO Annual Meeting

Hematologists Highlight Notable Insights From the 2025 EHA Congress

Post Hoc Analysis Shows Imetelstat Drives Benefit in RS-Negative, Lower-Risk MDS

Bexobrutideg Is Tolerable and Yields High Response Rates in Relapsed/Refractory Waldenström Macroglobulinemia

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

Navigating Toxicities in CAR T-Cell Therapy in R/R DLBCL

EP: 1.Overview of First-Line Treatment in Diffuse Large B-Cell Lymphoma

EP: 2.Evolving Practice Standards and Disease Progression Beyond Frontline Therapy for Patients with DLBCL

EP: 3.Treatment Selection in Second Line R/R DLBCL

EP: 4.Tafasitamab and Lenalidomide for R/R DLBCL

EP: 5.Real-World Outcomes of Tafasitamab-Lenalidomide for Patients with R/R DLBCL

EP: 6.The Role of CAR T-Cell Therapy in R/R DLBCL

EP: 7.Data Updates: CAR T in the ZUMA-7 and TRANSFORM Trials for R/R DLBCL

EP: 8.Clinical Perspectives of CAR T in R/R Diffuse Large B-Cell Lymphoma

EP: 9.Navigating Toxicities in CAR T-Cell Therapy in R/R DLBCL

EP: 10.Relapsed/Refractory DLBCL: Therapeutic Options in the Third Line Setting

EP: 11.Bispecifics for Third Line Therapy of R/R DLBCL

EP: 12.R/R DLBCL: Safety Considerations for Bispecific Antibodies

EP: 13.Treatment Sequencing of Later Line Therapies in R/R DLBCL

EP: 14.Additional Data Updates from ASH 2023

EP: 15.Future Outlooks in the Treatment of R/R DLBCL

Newsletter

Latest CME

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Latest Conference Coverage